Howard S. Jonas CEO and Chairman
Howard Jonas, CEO and Chairman of Lipomedix brings >30-year experience as founder and CEO of multi-billion-dollar corporation IDT. Chairman of the Board of Directors of Rafael holdings and served as Chief Executive Officer. Mr. Jonas has been a director of Rafael Pharmaceuticals since April 2013 and was appointed Chairman of the Board in April 2016. Serial entrepreneur with B.A. in Economics from Harvard University.
Eliyahu Shalom Deputy CEO
Eliyahu Shalom is an experienced business executive originally from NY. He brings vast experience across various sectors (tech, publishing, pharma). BSc in Business Management and a B.B.AA in Marketing from Brooklyn College.
Alberto Gabizon, MD, PhD, (Founder), President
Alberto Gabizon, founder, President and Chief Scientist of LipoMedix is Professor of Oncology (Shaare Zedek Medical Center, The Hebrew University of Jerusalem) and a renowned scientist and clinician in the field of nanomedicine and cancer therapy.
As co-inventor and co-developer of Doxil®, a smart chemotherapy "drug carrier" with tumor-targeting properties and important safety advantages, Prof. Gabizon is one of the few scientists intimately familiar with the successful development and the clinical implementation of liposomal drugs. His most recent invention currently in clinical studies is Promitil® (pegylated liposomal mitomycin-C prodrug).
Dr. Gabizon received his M.D. from the University of Granada in Spain, and his Ph.D. from the Weizmann Institute of Science in Israel. His clinical and research contributions in the field of liposomes and targeting therapy of cancers have been recognized by various awards among them the 2010 Alec Bangham Lifetime Achievement Award at the Liposome Research Days Conference in Vancouver, Canada, and the 1997 Kaye Innovation Award.
Patricia Ohana, PhD, VP Clinical Affairs
Dr. Patricia Ohana brings to LipoMedix over 20 years of experience and successful record in translating a product from pre-clinical to clinical stage in the development of anti-cancer drugs.
Prior to joining LipoMedix, Dr. Ohana most recently served as the Vice President of Research and Development and earlier, the Vice President of Clinical Development of BioCancell a biotech company dedicated to the development of DNA based drugs for the treatment of cancer. There she directed the development of their therapeutic product into multinational clinical trials. She previously held a position as research scientist in the Department of Biological Chemistry at the Hebrew University where she had a key role in the development of BC-819 as a drug for the treatment of cancer.
Dr. Ohana holds a PhD and a post-doctoral degree in Biological Chemistry from the Institute of Life Sciences at the Hebrew University of Jerusalem. She brings expertise in the field of biochemistry, molecular biology, oncology, DNA scale–up production, clinical development.